Skip Nav Destination
Evolution of a chemosensitive core-binding factor AML into an aggressive leukemia with eosinophilic differentiation
Low-dose cytarabine to prevent myeloid leukemia in children with Down syndrome: TMD Prevention 2007 study
Up-front rituximab maintenance improves outcome in patients with follicular lymphoma: a collaborative Nordic study
Impact of post-ASCT maintenance therapy on outcomes in patients with newly diagnosed multiple myeloma in Connect MM
Analysis of carfilzomib cardiovascular safety profile across relapsed and/or refractory multiple myeloma clinical trials
Phase 1 investigation of lenalidomide/rituximab plus outcomes of lenalidomide maintenance in relapsed CNS lymphoma
Ten-year outcome of patients with acute myeloid leukemia not treated with allogeneic transplantation in first complete remission
Allogeneic transplantation using TLI-ATG conditioning for Hodgkin lymphoma after failure of autologous transplantation
Issue Archive
Table of Contents
EXCEPTIONAL CASE REPORT
Evolution of a chemosensitive core-binding factor AML into an aggressive leukemia with eosinophilic differentiation
Clinical Trials & Observations
Wenbin Xiao,Mariko Yabe,Michael Offin,Pallavi Khattar,Jeeyeon Baik,Ryan J. Daley,Jeremy J. Pappacena,Mikhail Roshal,Yanming Zhang,Martin S. Tallman,Sheng F. Cai
STIMULUS REPORTS
Human adult HSCs can be discriminated from lineage-committed HPCs by the expression of endomucin
Kristian Reckzeh,Hüsün Kizilkaya,Alexandra Søgaard Helbo,Montserrat Estruch Alrich,André Gundersen Deslauriers,Amit Grover,Nicolas Rapin,Fazila Asmar,Kirsten Grønbæk,Bo Porse,Niels Borregaard,Dietmar Vestweber,Claus Nerlov,Kim Theilgaard-Mönch
CLINICAL TRIALS AND OBSERVATIONS
Low-dose cytarabine to prevent myeloid leukemia in children with Down syndrome: TMD Prevention 2007 study
Clinical Trials & Observations
Marius Flasinski,Kira Scheibke,Martin Zimmermann,Ursula Creutzig,Katarina Reinhardt,Femke Verwer,Valerie de Haas,Vincent H. J. van der Velden,Christine von Neuhoff,C. Michel Zwaan,Dirk Reinhardt,Jan-Henning Klusmann
Up-front rituximab maintenance improves outcome in patients with follicular lymphoma: a collaborative Nordic study
Clinical Trials & Observations
C. Madsen,M. R. Clausen,T. L. Plesner,A. Pasanen,T. Kuismanen,H. H. Bentzen,J. M. Jørgensen,I. B. Sillesen,B. M. Himmelstrup,D. Rønnov-Jessen,K. R. Jensen,A. M. Pettinger,M. Ludvigsen,S. Leppä,F. A. d’Amore
Impact of post-ASCT maintenance therapy on outcomes in patients with newly diagnosed multiple myeloma in Connect MM
Clinical Trials & Observations
Sundar Jagannath,Rafat Abonour,Brian G. M. Durie,Mohit Narang,Howard R. Terebelo,Cristina J. Gasparetto,Kathleen Toomey,James W. Hardin,Lynne Wagner,Amit Agarwal,Shankar Srinivasan,Amani Kitali,E. Dawn Flick,Michael Sturniolo,Robert M. Rifkin
Analysis of carfilzomib cardiovascular safety profile across relapsed and/or refractory multiple myeloma clinical trials
Clinical Trials & Observations
Ajai Chari,A. Keith Stewart,Stuart D. Russell,Philippe Moreau,Joerg Herrmann,Jose Banchs,Roman Hajek,John Groarke,Alexander R. Lyon,George N. Batty,Sunhee Ro,Mei Huang,Karim S. Iskander,Daniel Lenihan
LYMPHOID NEOPLASIA
Phase 1 investigation of lenalidomide/rituximab plus outcomes of lenalidomide maintenance in relapsed CNS lymphoma
Clinical Trials & Observations
James L. Rubenstein,Huimin Geng,Eleanor J. Fraser,Paul Formaker,Lingjing Chen,Jigyasa Sharma,Phoebe Killea,Kaylee Choi,Jenny Ventura,John Kurhanewicz,Clifford Lowell,Jimmy Hwang,Patrick Treseler,Penny K. Sneed,Jing Li,Xiaomin Wang,Nianhang Chen,Jon Gangoiti,Pamela N. Munster,Bertil Damato
Partial trisomy 21 contributes to T-cell malignancies induced by JAK3-activating mutations in murine models
Paola Rivera-Munoz,Anouchka P. Laurent,Aurelie Siret,Cecile K. Lopez,Cathy Ignacimouttou,Melanie G. Cornejo,Olivia Bawa,Philippe Rameau,Olivier A. Bernard,Philippe Dessen,Gary D. Gilliland,Thomas Mercher,Sébastien Malinge
MYELOID NEOPLASIA
Telomere shortening correlates with leukemic stem cell burden at diagnosis of chronic myeloid leukemia
Anne-Sophie Bouillon,Monica S. Ventura Ferreira,Shady Adnan Awad,Johan Richter,Andreas Hochhaus,Volker Kunzmann,Jolanta Dengler,Jeroen Janssen,Gert Ossenkoppele,Peter E. Westerweel,Peter A. W. te Boekhorst,Francois-Xavier Mahon,Henrik Hjorth-Hansen,Susanne Isfort,Thoas Fioretos,Sebastian Hummel,Mirle Schemionek,Stefan Wilop,Steffen Koschmieder,Susanne Saußele,Satu Mustjoki,Fabian Beier,Tim H. Brümmendorf
Ten-year outcome of patients with acute myeloid leukemia not treated with allogeneic transplantation in first complete remission
Clinical Trials & Observations
Sumithira Vasu,Jessica Kohlschmidt,Krzysztof Mrózek,Ann-Kathrin Eisfeld,Deedra Nicolet,Lisa J. Sterling,Heiko Becker,Klaus H. Metzeler,Dimitrios Papaioannou,Bayard L. Powell,Jonathan E. Kolitz,Joseph O. Moore,Maria R. Baer,Gail J. Roboz,Richard M. Stone,John C. Byrd,Andrew J. Carroll,Clara D. Bloomfield
THROMBOSIS AND HEMOSTASIS
The common VWF single nucleotide variants c.2365A>G and c.2385T>C modify VWF biosynthesis and clearance
Ahmad H. Mufti,on behalf of the European Group on von Willebrand disease (EU-VWD) and Zimmerman Program for the Molecular and Clinical Biology of von Willebrand disease (ZPMCB-VWD) Study Groups,Kenichi Ogiwara,on behalf of the European Group on von Willebrand disease (EU-VWD) and Zimmerman Program for the Molecular and Clinical Biology of von Willebrand disease (ZPMCB-VWD) Study Groups,Laura L. Swystun,on behalf of the European Group on von Willebrand disease (EU-VWD) and Zimmerman Program for the Molecular and Clinical Biology of von Willebrand disease (ZPMCB-VWD) Study Groups,Jeroen C. J. Eikenboom,on behalf of the European Group on von Willebrand disease (EU-VWD) and Zimmerman Program for the Molecular and Clinical Biology of von Willebrand disease (ZPMCB-VWD) Study Groups,Ulrich Budde,on behalf of the European Group on von Willebrand disease (EU-VWD) and Zimmerman Program for the Molecular and Clinical Biology of von Willebrand disease (ZPMCB-VWD) Study Groups,Wilma M. Hopman,on behalf of the European Group on von Willebrand disease (EU-VWD) and Zimmerman Program for the Molecular and Clinical Biology of von Willebrand disease (ZPMCB-VWD) Study Groups,Christer Halldén,on behalf of the European Group on von Willebrand disease (EU-VWD) and Zimmerman Program for the Molecular and Clinical Biology of von Willebrand disease (ZPMCB-VWD) Study Groups,Jenny Goudemand,on behalf of the European Group on von Willebrand disease (EU-VWD) and Zimmerman Program for the Molecular and Clinical Biology of von Willebrand disease (ZPMCB-VWD) Study Groups,Ian R. Peake,on behalf of the European Group on von Willebrand disease (EU-VWD) and Zimmerman Program for the Molecular and Clinical Biology of von Willebrand disease (ZPMCB-VWD) Study Groups,Anne C. Goodeve,on behalf of the European Group on von Willebrand disease (EU-VWD) and Zimmerman Program for the Molecular and Clinical Biology of von Willebrand disease (ZPMCB-VWD) Study Groups,David Lillicrap,on behalf of the European Group on von Willebrand disease (EU-VWD) and Zimmerman Program for the Molecular and Clinical Biology of von Willebrand disease (ZPMCB-VWD) Study Groups,Daniel J. Hampshire,on behalf of the European Group on von Willebrand disease (EU-VWD) and Zimmerman Program for the Molecular and Clinical Biology of von Willebrand disease (ZPMCB-VWD) Study Groups
TRANSFUSION MEDICINE
Gastrointestinal microbiota contributes to the development of murine transfusion-related acute lung injury
Rick Kapur,Michael Kim,Johan Rebetz,Björn Hallström,Jonas T. Björkman,Alisa Takabe-French,Noel Kim,Jonathan Liu,Shanjeevan Shanmugabhavananthan,Stefan Milosevic,Mark J. McVey,Edwin R. Speck,John W. Semple
COMMENTARY
Allogeneic transplantation using TLI-ATG conditioning for Hodgkin lymphoma after failure of autologous transplantation
Clinical Trials & Observations
ERRATUM
-
Cover Image
Cover Image
COVER FIGURE
Photomicrograph demonstrating protein expression of indoleamine 2,3-dioxygenase 1 (IDO1) in a diagnostic specimen of primary central nervous system (CNS) lymphoma (original magnification ×1000). IDO1 immunoreactivity was evident on lymphoma cells as well as tumor-associated CD163+ alternatively activated macrophages. Endothelial cells within the tumor vasculature were IDO1 negative. Transcriptional upregulation of IDO1 in cases of primary CNS lymphoma was confirmed. See the article by Rubenstein et al. - PDF Icon PDF LinkFront Matter
- PDF Icon PDF LinkEditorial Board
Advertisement intended for health care professionals
Advertisement intended for health care professionals